PrEP-aring the General Gynecologist to Offer HIV Pre-exposure Prophylaxis.
Journal
Clinical obstetrics and gynecology
ISSN: 1532-5520
Titre abrégé: Clin Obstet Gynecol
Pays: United States
ID NLM: 0070014
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
pubmed:
17
6
2022
medline:
22
10
2022
entrez:
16
6
2022
Statut:
ppublish
Résumé
It is estimated that 450,000 American women are at increased risk of infection with human immunodeficiency virus (HIV), and yet only 7% have a prescription for pre-exposure prophylaxis (PrEP). PrEP is a safe and effective method of HIV infection prevention via a daily use of an oral combination antiretroviral pill or longer-acting intramuscular injections. Gynecologists are experts in women's sexual health, and provide over half of annual preventative health visits, but are not yet routinely providing PrEP to patients, citing lack of knowledge as a major barrier. The authors aim to provide the general gynecologist with the skills to expertly provide PrEP to their patients to reduce HIV infection.
Identifiants
pubmed: 35708963
doi: 10.1097/GRF.0000000000000713
pii: 00003081-202212000-00007
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
733-738Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Centers for Disease Control and Prevention. HIV surveillance report, 2019. 2021. Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html . Accessed January 10, 2022.
US Department of Health and Human Services. HIV National Strategic Plan for the United States: a roadmap to end the epidemic 2021–2025. 2021. Available at: https://files.hiv.gov/s3fs-public/HIV-National-Strategic-Plan-2021-2025.pdf . Accessed January 10, 2022.
Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, 2nd ed. Geneva: World Health Organization; 2016.
HIV Prevention Trials Network. HPTN 084 study demonstrates superiority of CAB LA to oral TDF/FTC for the prevention of HIV. The HIV Prevention Trials Network. 2022. Available at: https://www.hptn.org/news-and-events/press-releases/hptn-084-study-demonstrates-superiority-of-cab-la-to-oral-tdfftc-for . Accessed February 2, 2022.
Centers for Disease Control and Prevention. US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. 2021. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf . Accessed January 11, 2022.
ACOG Committee Opinion No. 755: well-woman visit. Obstet Gynecol. 2018;132:e181–e186.
US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, et al. Screening for chlamydia and gonorrhea: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326:949.
US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for intimate partner violence, elder abuse, and abuse of vulnerable adults: US Preventive Services Task Force Final Recommendation Statement. JAMA. 2018;320:1678.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, et al. Screening for HIV infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;321:2326.
Women’s Preventive Services Initiative. Recommendations for preventive services for women: final report to the U.S. Department of Health and Human Services, Health Resources & Services Administration. Am Coll Obstet Gynecol. 2016. Available at: https://womenspreventivehealth.org/wp-content/uploads/WPSI_2016FullReport.pdf . Accessed January 10, 2022.
Auerbach JD, Kinsky S, Brown G, et al. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDs. 2015;29:102–110.
Simoncini GM, Koren DE, DʼAvanzo PA, et al. Physician survey results: clinical practice training is needed to improve Ob/Gyn PrEP adoption [02A]. Obstet Gynecol. 2020;135:9S.
Kole M, Scott M, Brar I, et al. Do you PrEP? Knowledge and practice among obstetrician and gynecologists in an inner city hospital [16Q]. Obstet Gynecol. 2019;133:185S–185S.
Seidman D, Carlson K, Weber S, et al. United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: a national survey. Contraception. 2016;93:463–469.
Apretude [package insert] [Internet]. Research Triangle Park, NC: ViiV Healthcare; 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215499s000lbl.pdf . Accessed February 1, 2022.
Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. 2022. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf . Accessed January 18, 2022.
Lampe MA, Smith DK, Anderson GJE, et al. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol. 2011;204:488.e1–488.e8.
Ehrhardt S, Xie C, Guo N, et al. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis. 2015;60:275–278.